Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer
Status:
Terminated
Trial end date:
2017-04-08
Target enrollment:
Participant gender:
Summary
Determine the safety of a combination of IFN, celecoxib, and rintatolimod for patients with
recurrent colorectal cancer. This will also test whether the above combination can help the
immune system to fight the tumors. The results will allow the investigators to determine the
"preferred" combination for subsequent extended studies.